| Outcome Measures: |
Primary: Endothelial Function, Differences in fenofibrate induced-changes in Reactive Hyperemia Index (RHI) across rs6008845 genotypes. \[RHI is a non-invasive measure of endothelial function, and it is inversely associated with risk of cardiovascular disease\]., baseline and 12 weeks | Secondary: Arterial Stiffness - Pulse Wave Velocity (PWV), Differences in fenofibrate induced-changes in PWV across rs6008845 genotypes. \[PWV is directly associated with risk of cardiovascular disease\], baseline and 12 weeks|Endothelial progenitor cells (EPCs), Differences in fenofibrate induced-changes in circulating levels of EPC across rs6008845 genotypes., baseline and 12 weeks|Inflammatory markers and chemokines, Differences in fenofibrate induced-changes in CCL11, CCL27 sVCAM, sE-Selectin, Endothelin-1 across rs6008845 genotypes., baseline and 12 weeks|Platelet aggregation induced by adenosine diphosphate (ADP), Anti-platelet effects will be evaluated as the differences in fenofibrate induced-changes in platelet aggregation induced by adenosine diphosphate (ADP) (i.e. ADPtest) across rs6008845 genotypes., baseline and 12 weeks|Platelet aggregation induced by arachidonic acid, Anti-platelet effects will be evaluated as the differences in fenofibrate induced-changes in platelet aggregation induced by arachidonic acid (ASPI test) across rs6008845 genotypes., baseline and 12 weeks | Other: Arterial Stiffness - Augmentation Index (AI), Differences in fenofibrate induced-changes in AI across rs6008845 genotypes, Baseline and 12 weeks|Haematopoietic stem/progenitor cells (HSPCs), Differences in fenofibrate induced-changes in circulating levels of HSPC across rs6008845 genotypes., Baseline and 12 weeks
|
